Research ExplorerPublicationsEpidemiology of invasive aspergillosis and azole resistance ...

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study

Standard

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study. / Koehler, Philipp; Hamprecht, Axel; Bader, Oliver; Bekeredjian-Ding, Isabelle; Buchheidt, Dieter; Doelken, Gottfried; Elias, Johannes; Haase, Gerhard; Hahn-Ast, Corinna; Karthaus, Meinolf; Kekulé, Alexander; Keller, Peter; Kiehl, Michael; Krause, Stefan W; Krämer, Carolin; Neumann, Silke; Rohde, Holger; La Rosée, Paul; Ruhnke, Markus; Schafhausen, Philippe; Schalk, Enrico; Schulz, Katrin; Schwartz, Stefan; Silling, Gerda; Staib, Peter; Ullmann, Andrew; Vergoulidou, Maria; Weber, Thomas; Cornely, Oliver A; Vehreschild, Maria J G T.

In: INT J ANTIMICROB AG, Vol. 49, No. 2, 02.2017, p. 218-223.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Koehler, P, Hamprecht, A, Bader, O, Bekeredjian-Ding, I, Buchheidt, D, Doelken, G, Elias, J, Haase, G, Hahn-Ast, C, Karthaus, M, Kekulé, A, Keller, P, Kiehl, M, Krause, SW, Krämer, C, Neumann, S, Rohde, H, La Rosée, P, Ruhnke, M, Schafhausen, P, Schalk, E, Schulz, K, Schwartz, S, Silling, G, Staib, P, Ullmann, A, Vergoulidou, M, Weber, T, Cornely, OA & Vehreschild, MJGT 2017, 'Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study', INT J ANTIMICROB AG, vol. 49, no. 2, pp. 218-223. https://doi.org/10.1016/j.ijantimicag.2016.10.019

APA

Koehler, P., Hamprecht, A., Bader, O., Bekeredjian-Ding, I., Buchheidt, D., Doelken, G., Elias, J., Haase, G., Hahn-Ast, C., Karthaus, M., Kekulé, A., Keller, P., Kiehl, M., Krause, S. W., Krämer, C., Neumann, S., Rohde, H., La Rosée, P., Ruhnke, M., ... Vehreschild, M. J. G. T. (2017). Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study. INT J ANTIMICROB AG, 49(2), 218-223. https://doi.org/10.1016/j.ijantimicag.2016.10.019

Vancouver

Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study. INT J ANTIMICROB AG. 2017 Feb;49(2):218-223. https://doi.org/10.1016/j.ijantimicag.2016.10.019

Bibtex

@article{e88b12dc91e64cb4914971f5d16f1fe7,
title = "Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study",
abstract = "Invasive aspergillosis (IA) is a serious hazard to high-risk haematological patients. There are increasing reports of azole-resistant Aspergillus spp. This study assessed the epidemiology of IA and azole-resistant Aspergillus spp. in patients with acute leukaemia in Germany. A prospective multicentre cohort study was performed in German haematology/oncology centres. The incidence of probable and proven aspergillosis according to the revised EORTC/MSG criteria was assessed for all patients with acute leukaemia [acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL)]. Cases were documented into a web-based case report form, and centres provided data on standards regarding prophylactic and diagnostic measures. Clinical isolates were screened centrally for azole resistance and, if applicable, underlying resistance mechanisms were analysed. Between September 2011 and December 2013, 179 cases of IA [6 proven (3.4%) and 173 probable (96.6%)] were diagnosed in 3067 patients with acute leukaemia. The incidence of IA was 6.4% among 2440 AML patients and 3.8% among 627 ALL patients. Mortality at Day 84 was 33.8% (49/145) and attributable mortality was 26.9% (39/145). At Day 84, 53 patients (29.6%) showed a complete response, 25 (14.0%) a partial response and 17 (9.5%) a deterioration or failure. A total of 77 clinical Aspergillus fumigatus isolates were collected during the study period. Two episodes of azole-resistant IA (1.1%) were caused by a TR/L98H mutation in the cyp51A gene. With only two cases of IA due to azole-resistant A. fumigatus, a change of antifungal treatment practices in Germany does not appear warranted currently.",
author = "Philipp Koehler and Axel Hamprecht and Oliver Bader and Isabelle Bekeredjian-Ding and Dieter Buchheidt and Gottfried Doelken and Johannes Elias and Gerhard Haase and Corinna Hahn-Ast and Meinolf Karthaus and Alexander Kekul{\'e} and Peter Keller and Michael Kiehl and Krause, {Stefan W} and Carolin Kr{\"a}mer and Silke Neumann and Holger Rohde and {La Ros{\'e}e}, Paul and Markus Ruhnke and Philippe Schafhausen and Enrico Schalk and Katrin Schulz and Stefan Schwartz and Gerda Silling and Peter Staib and Andrew Ullmann and Maria Vergoulidou and Thomas Weber and Cornely, {Oliver A} and Vehreschild, {Maria J G T}",
note = "Copyright {\textcopyright} 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.",
year = "2017",
month = feb,
doi = "10.1016/j.ijantimicag.2016.10.019",
language = "English",
volume = "49",
pages = "218--223",
journal = "INT J ANTIMICROB AG",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study

AU - Koehler, Philipp

AU - Hamprecht, Axel

AU - Bader, Oliver

AU - Bekeredjian-Ding, Isabelle

AU - Buchheidt, Dieter

AU - Doelken, Gottfried

AU - Elias, Johannes

AU - Haase, Gerhard

AU - Hahn-Ast, Corinna

AU - Karthaus, Meinolf

AU - Kekulé, Alexander

AU - Keller, Peter

AU - Kiehl, Michael

AU - Krause, Stefan W

AU - Krämer, Carolin

AU - Neumann, Silke

AU - Rohde, Holger

AU - La Rosée, Paul

AU - Ruhnke, Markus

AU - Schafhausen, Philippe

AU - Schalk, Enrico

AU - Schulz, Katrin

AU - Schwartz, Stefan

AU - Silling, Gerda

AU - Staib, Peter

AU - Ullmann, Andrew

AU - Vergoulidou, Maria

AU - Weber, Thomas

AU - Cornely, Oliver A

AU - Vehreschild, Maria J G T

N1 - Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

PY - 2017/2

Y1 - 2017/2

N2 - Invasive aspergillosis (IA) is a serious hazard to high-risk haematological patients. There are increasing reports of azole-resistant Aspergillus spp. This study assessed the epidemiology of IA and azole-resistant Aspergillus spp. in patients with acute leukaemia in Germany. A prospective multicentre cohort study was performed in German haematology/oncology centres. The incidence of probable and proven aspergillosis according to the revised EORTC/MSG criteria was assessed for all patients with acute leukaemia [acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL)]. Cases were documented into a web-based case report form, and centres provided data on standards regarding prophylactic and diagnostic measures. Clinical isolates were screened centrally for azole resistance and, if applicable, underlying resistance mechanisms were analysed. Between September 2011 and December 2013, 179 cases of IA [6 proven (3.4%) and 173 probable (96.6%)] were diagnosed in 3067 patients with acute leukaemia. The incidence of IA was 6.4% among 2440 AML patients and 3.8% among 627 ALL patients. Mortality at Day 84 was 33.8% (49/145) and attributable mortality was 26.9% (39/145). At Day 84, 53 patients (29.6%) showed a complete response, 25 (14.0%) a partial response and 17 (9.5%) a deterioration or failure. A total of 77 clinical Aspergillus fumigatus isolates were collected during the study period. Two episodes of azole-resistant IA (1.1%) were caused by a TR/L98H mutation in the cyp51A gene. With only two cases of IA due to azole-resistant A. fumigatus, a change of antifungal treatment practices in Germany does not appear warranted currently.

AB - Invasive aspergillosis (IA) is a serious hazard to high-risk haematological patients. There are increasing reports of azole-resistant Aspergillus spp. This study assessed the epidemiology of IA and azole-resistant Aspergillus spp. in patients with acute leukaemia in Germany. A prospective multicentre cohort study was performed in German haematology/oncology centres. The incidence of probable and proven aspergillosis according to the revised EORTC/MSG criteria was assessed for all patients with acute leukaemia [acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL)]. Cases were documented into a web-based case report form, and centres provided data on standards regarding prophylactic and diagnostic measures. Clinical isolates were screened centrally for azole resistance and, if applicable, underlying resistance mechanisms were analysed. Between September 2011 and December 2013, 179 cases of IA [6 proven (3.4%) and 173 probable (96.6%)] were diagnosed in 3067 patients with acute leukaemia. The incidence of IA was 6.4% among 2440 AML patients and 3.8% among 627 ALL patients. Mortality at Day 84 was 33.8% (49/145) and attributable mortality was 26.9% (39/145). At Day 84, 53 patients (29.6%) showed a complete response, 25 (14.0%) a partial response and 17 (9.5%) a deterioration or failure. A total of 77 clinical Aspergillus fumigatus isolates were collected during the study period. Two episodes of azole-resistant IA (1.1%) were caused by a TR/L98H mutation in the cyp51A gene. With only two cases of IA due to azole-resistant A. fumigatus, a change of antifungal treatment practices in Germany does not appear warranted currently.

U2 - 10.1016/j.ijantimicag.2016.10.019

DO - 10.1016/j.ijantimicag.2016.10.019

M3 - SCORING: Journal article

C2 - 27989379

VL - 49

SP - 218

EP - 223

JO - INT J ANTIMICROB AG

JF - INT J ANTIMICROB AG

SN - 0924-8579

IS - 2

ER -